Skyrizi is approved for moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. AbbVie said the annual wholesale cost for maintenance dosing of ...

"Skyrizi has the potential to help psoriasis patients achieve high rates of skin clearance, bringing them closer to reaching long-term treatment goals with every 12-week dosing." ...

People taking Skyrizi in clinical trials didn’t report having depression. However, it’s important to note that plaque psoriasis and depression may have links. (Skyrizi is approved to treat ...